JPMorgan has issued a research report raising the H-share target price for CMSC (06099) from HK$20.5 to HK$21, while keeping an "Overweight" rating. The bank believes that CMSC will have an opportunity to revalue its investment gains from CXMT (688825.SH) ahead of the third-quarter earnings season. Amid a generally weaker trading environment and slowing margin financing trends across the brokerage sector in Q3, CMSC stands out as one of the few Chinese securities firms with a clear company-specific earnings catalyst.

JPMorgan points out that CMSC holds the largest exposure to CXMT among Chinese brokerages, involving approximately RMB 27 billion in unrealized gains. However, its analysis suggests that only part of this value is currently reflected in the stock price. The bank estimates that as brokerages begin recognizing related investment income following CXMT's listing in July, CMSC's third-quarter earnings could grow approximately 190% year-over-year, significantly outperforming its peers.

CMSC's outperformance relative to its peers has narrowed since its July peak, and JPMorgan sees this as a buying opportunity ahead of the Q3 earnings catalyst. The bank notes that CMSC holds 505 million shares of CXMT, representing 0.74% of the total issued shares, which translates to approximately RMB 27 billion in unrealized gains based on its calculations—equivalent to about 2.2 times its projected 2025 net profit. CXMT listed on the Shanghai Stock Exchange on July 27, 2026, and brokerages will begin recognizing part of the investment income in their Q3 results, though the position remains under a lock-up period and must be accounted for with a liquidity discount.